Patent ID: 7709216
Filing Date: 2010-05-04
Classification: A01K,A61K,C07K,G01N

Abstract:
1. A method for identifying a drug which substantially inhibits the binding of PUMA to Bcl-2, the method comprising: a) providing a cardiomyocyte in vitro, said cardiomyocyte expressing PUMA and Bcl-2; b) providing a candidate drug to be tested for its ability to interfere with the binding of PUMA and Bcl-2; c) introducing said candidate drug to said cardiomyocyte; d) determining the extent of binding of PUMA and Bcl-2; and e) comparing the extent of binding determined in step d) to the extent of binding in an otherwise identical incubation in which no candidate drug is included, a substantial difference between the former and the latter indicating that the candidate drug is effective in substantially inhibiting the binding of PUMA to Bcl-2.